Dong, Jinrui
Viswanathan, Sivakumar
Adami, Eleonora
Singh, Brijesh K.
Chothani, Sonia P. http://orcid.org/0000-0002-1010-7069
Ng, Benjamin
Lim, Wei Wen http://orcid.org/0000-0003-0311-943X
Zhou, Jin
Tripathi, Madhulika
Ko, Nicole S. J.
Shekeran, Shamini G.
Tan, Jessie
Lim, Sze Yun
Wang, Mao http://orcid.org/0000-0001-7545-4048
Lio, Pei Min
Yen, Paul M.
Schafer, Sebastian http://orcid.org/0000-0002-6909-8275
Cook, Stuart A. http://orcid.org/0000-0001-6628-194X
Widjaja, Anissa A. http://orcid.org/0000-0001-9404-7608
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/CIRG/1457/2016, NMRC/STaR/0029/2017, NMRC Centre Grant to the NHCS, MOH‐CIRG18nov‐0002, NMRC/OFYIRG/0053/2017)
Article History
Received: 18 March 2020
Accepted: 24 November 2020
First Online: 4 January 2021
Competing interests
: S.A.C., S.S., A.A.W., B.N., W.W.L., and B.K.S. are co-inventors on a number of patent applications relating to the role of IL11 in human diseases that include the published patents: WO2017103108, WO2017103108 A2, WO 2018/109174 A2, WO 2018/109170 A2. S.A.C. and S.S. are co-founders and shareholders of Enleofen Bio PTE LTD, a company (which S.A.C. is a director of) that developed anti-IL11 therapeutics, which were acquired for further development by Boehringer Ingelheim. All other authors declare non-competing interests.